The European Medicines Agency’s scientific committee, the CHMP, has given the thumbs-up to Samsung Bioepis’s Ontruzant (formerly known as SB3), a biosimilar version of Roche’s breast cancer treatment Herceptin (trastuzumab).
Provided the positive opinion is converted into a marketing authorization by the European Commission, this will be the first biosimilar...






